U.S. markets open in 1 hour 50 minutes

Cytokinetics, Incorporated (CYTK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.55+0.24 (+1.08%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close22.31
Open22.50
Bid21.66 x 800
Ask23.51 x 800
Day's Range22.25 - 22.99
52 Week Range14.71 - 30.14
Volume358,744
Avg. Volume745,758
Market Cap1.618B
Beta (5Y Monthly)1.37
PE Ratio (TTM)N/A
EPS (TTM)-2.00
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.64
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Cytokinetics Announces Three Presentations to Occur at the European Society of Cardiology Heart Failure 2021 Congress
    GlobeNewswire

    Cytokinetics Announces Three Presentations to Occur at the European Society of Cardiology Heart Failure 2021 Congress

    SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced three presentations at Heart Failure 2021, an International Congress of the European Society of Cardiology taking place online from June 29, 2021 – July 1, 2021. The presentations will include a Late Breaking Clinical Trial Session with additional analyses from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) re

  • Cytokinetics Announces Completion of Enrollment in METEORIC-HF, The Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure With Reduced Ejection Fraction
    GlobeNewswire

    Cytokinetics Announces Completion of Enrollment in METEORIC-HF, The Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure With Reduced Ejection Fraction

    Top Line Results of METEORIC-HF Expected in Early 2022 Company Plans to Submit NDA in 2H 2021 Based on Positive Results of GALACTIC-HF SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the completion of patient enrollment in METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil. METEORIC-HF is d

  • Cytokinetics to Participate in Upcoming Investor Conferences
    GlobeNewswire

    Cytokinetics to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in three virtual fireside chats at the following investor conferences: 42nd Annual Goldman Sachs Healthcare Conference on Wednesday, June 9, 2021 at 3:00 PM EDTJMP Securities Life Sciences Conference on Wednesday, June 16, 2021 at 4:00 PM EDTRaymond James Human Health Innovation Conference